BioInvent International AB BINV

Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties of BI-1808 and BI-1910 across diverse tumor microenvironments Data demonstrates the ability of the lead anti-TNFR2 antibody ...

Oslo, 17 August 2026: The Board of Directors of Zelluna ASA (the “Company”) hereby calls for an Extraordinary General Meeting to be held on 9 September 2026 at 13:00 CEST, regarding election of a new member of the Company’s Board of Directors (the “Board”). The Nomination Committee has proposed Martin Welschof for election as a new member of the Board. Martin Welschof is CEO of BioInvent International AB (Nasdaq Stockholm) and has previously served as CEO of Affitech A/S and Opsona Therapeutics.

FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer. BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR and 56% DCR in heavily pretreated patients with advanced ...

LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV) Preclinical proof-of-concept data support two distinct FcγR-blockade strategies to enhance cancer antibody therapies and overcome resistance BI-1206 boosts αPD-1 antibody ...

LUND, SE / ACCESS Newswire / July 17, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its abstract describing BI-1808 in recurrent platinum-resistant ...

The metastatic HER2-positive breast cancer market outlook continues to be promising, supported by ongoing innovation, expanding therapeutic indications, lifecycle management initiatives, and increasing demand for more effective and patient-friendly HER2-targeted treatments, including SYD985 (trastuzumab duocarmazine) (Byondis), Giredestrant (Roche), ARX788 (Ambrx), IBRANCE (palbociclib) (Pfizer), BDC-1001 ± pertuzumab (Bolt Biotherapeutics), BI-1607 + Trastuzumab (BioInvent International AB), an

LUND, SE / ACCESS Newswire / June 1, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it will host an in-person and virtual key opinion leader ...

LUND, SE / ACCESS Newswire / April 29, 2026 / The Annual General Meeting (AGM) of BioInvent International AB (BioInvent) (Nasdaq Stockholm:BINV) resolved to elect Kate Hermans and Scott Zinober as new Board members, re-elect the Board members Natalie ...

Events will feature expert perspectives on BI-1808 in ovarian cancer and T‑cell lymphomas, and BI-1206 for the treatment of NHL LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader ...

LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), ...

LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, ...

BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel ...

LUND, SE / ACCESS Newswire / March 24, 2026 / BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m. CEST, 29 ...

XOMA Royalty (NASDAQ:XOMA) executives used the company’s 2025 financial results call to emphasize a year of portfolio expansion, rising royalty receipts, and what management described as progress toward a business model in which recurring royalties can cover core operating costs. Management highlig